{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:51:56Z","timestamp":1781221916559,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ashjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.jash.2016.05.013","type":"journal-article","created":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T23:08:04Z","timestamp":1465686484000},"page":"671-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"10","author":[{"given":"Jie V.","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Mary","family":"Schooling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2016.05.013_bib1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2016.05.013_bib2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/eci.12342","article-title":"Why do statins reduce cardiovascular disease more than other lipid modulating therapies?","volume":"44","author":"Schooling","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jash.2016.05.013_bib3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/jch.12679","article-title":"Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials","volume":"18","author":"Zhang","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2016.05.013_bib4","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2016.05.013_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2016.05.013_bib6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2016.05.013_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jash.2016.05.013_bib8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2016.05.013_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2013.10.051","article-title":"Aldosterone aggravates glucose intolerance induced by high fructose","volume":"720","author":"Sherajee","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jash.2016.05.013_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2337\/db12-0905","article-title":"Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?","volume":"62","author":"Bender","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2016.05.013_bib11","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","article-title":"Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles","volume":"51","author":"Swaminathan","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.jash.2016.05.013_bib12","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2016.05.013_bib13","doi-asserted-by":"crossref","first-page":"E90","DOI":"10.1086\/656264","article-title":"Intra- and intersexual trade-offs between testosterone and immune system: Implications for sexual and sexually antagonistic selection","volume":"176","author":"Schroderus","year":"2010","journal-title":"Am Nat"},{"key":"10.1016\/j.jash.2016.05.013_bib14","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.ppat.1000267","article-title":"The sicker sex","volume":"5","author":"Zuk","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jash.2016.05.013_bib15","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1073\/pnas.1422041112","article-title":"Macronutrient balance, reproductive function, and lifespan in aging mice","volume":"112","author":"Solon-Biet","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jash.2016.05.013_bib16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.det.2010.03.011","article-title":"Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss","volume":"28","author":"Rathnayake","year":"2010","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jash.2016.05.013_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3949\/ccjm.57.3.285","article-title":"Use of spironolactone in treatment of hirsutism","volume":"57","author":"Cumming","year":"1990","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jash.2016.05.013_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00404-009-1051-y","article-title":"Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome","volume":"281","author":"Kebapcilar","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jash.2016.05.013_bib19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/1008-682X.122346","article-title":"Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Cai","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.jash.2016.05.013_bib20","unstructured":"PROSPERO International prospective register of systematic reviews. Available at: http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.asp?ID=CRD42013006908. Accessed January 12,\u00a02016."},{"key":"10.1016\/j.jash.2016.05.013_bib21","unstructured":"Imputing standard deviations for changes from baseline. Available at: http:\/\/handbook.cochrane.org\/chapter_16\/16_1_3_2_imputing_standard_deviations_for_changes_from_baseline.htm. Accessed January 12, 2016."},{"key":"10.1016\/j.jash.2016.05.013_bib22","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.2337\/diacare.26.10.2728","article-title":"Is HbA(1c) affected by glycemic instability?","volume":"26","author":"Derr","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2016.05.013_bib23","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","article-title":"The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus","volume":"51","author":"Verhagen","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jash.2016.05.013_bib24","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/jc.2013-1040","article-title":"Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study","volume":"98","author":"Ganie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jash.2016.05.013_bib25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.numecd.2013.04.016","article-title":"In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone","volume":"24","author":"Mazza","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jash.2016.05.013_bib26","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.jash.2016.05.013_bib27","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2016.05.013_bib28","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2016.05.013_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2215\/CJN.06330612","article-title":"Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes","volume":"8","author":"Viswanathan","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jash.2016.05.013_bib30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2337\/db14-0670","article-title":"Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes","volume":"64","author":"Garg","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2016.05.013_bib31","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.jash.2016.05.013_bib32","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2016.05.013_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ijcard.2013.12.039","article-title":"Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure","volume":"171","author":"Ogino","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2016.05.013_bib34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/1470320311402110","article-title":"Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease","volume":"12","author":"Polyzos","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jash.2016.05.013_bib35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.contraception.2011.12.011","article-title":"The effects of 2 mg chlormadinone acetate\/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome","volume":"86","author":"Vieira","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.jash.2016.05.013_bib36","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jash.2016.05.013_bib37","first-page":"2198","article-title":"Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women\u2013a clinical research center study","volume":"81","author":"Lovejoy","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jash.2016.05.013_bib38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ajh\/4.4.356","article-title":"Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty?","volume":"4","author":"Plouin","year":"1991","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2016.05.013_bib39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.12224","article-title":"Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects","volume":"16","author":"Garg","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jash.2016.05.013_bib40","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa0908359","article-title":"Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults","volume":"362","author":"Selvin","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2016.05.013_bib41","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2016.05.013_bib42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S2213-8587(15)00377-0","article-title":"Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial","volume":"4","author":"Brown","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jash.2016.05.013_bib43","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2016.05.013_bib44","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2016.05.013_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2016.05.013_bib46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/jhh.2014.19","article-title":"Effect of eplerenone on insulin action in essential hypertension: a randomised, controlled, crossover study","volume":"28","author":"McMurray","year":"2014","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2016.05.013_bib47","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1210\/jc.2005-1077","article-title":"Mortality in patients with Klinefelter syndrome in Britain: A cohort study","volume":"90","author":"Swerdlow","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jash.2016.05.013_bib48","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1177\/193229681100500634","article-title":"Is there a relationship between mean blood glucose and glycated hemoglobin?","volume":"5","author":"Makris","year":"2011","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jash.2016.05.013_bib49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","article-title":"Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases","volume":"327","author":"Wrenger","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2016.05.013_bib50","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","article-title":"Spironolactone use and the risk of breast and gynecologic cancers","volume":"37","author":"Biggar","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jash.2016.05.013_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","article-title":"Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes","volume":"95","author":"Kostis","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2016.05.013_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.amjcard.2004.08.063","article-title":"The debate goes on\u2013what is your choice?","volume":"95","author":"Gavras","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2016.05.013_bib53","doi-asserted-by":"crossref","first-page":"e001718","DOI":"10.1161\/JAHA.114.001718","article-title":"National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011","volume":"4","author":"Guan","year":"2015","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171116303278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171116303278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T03:53:09Z","timestamp":1536637989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171116303278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1933171116303278"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2016.05.013","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2016.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society of Hypertension. All rights reserved.","name":"copyright","label":"Copyright"}]}}